Free expedited shipping US board certified clinicians, all 50 states 24/7 unified patient care HSA · FSA eligible Compounded in the USA
← Living Vitality
Trellis Vitality Peptides

Tesamorelin Dosing, Honestly: Where 2 mg Comes From — and Why Many Protocols Run Lower

The only tesamorelin dose ever tested in large trials is 2 mg daily — for one condition. The lower doses common in longevity practice are clinical judgment, not published evidence. Here's the honest read.

Cover art: Tesamorelin Dosing, Honestly: Where 2 mg Comes From — and Why Many Protocols Run Lower

The only tesamorelin dose ever tested in large randomized trials is 2 mg once daily, subcutaneously — and it was tested for one specific condition: excess abdominal fat in HIV-associated lipodystrophy. The lower doses you see discussed in longevity settings, commonly 0.75 to 1 mg, were never tested in the large trials for those uses; they are clinical judgment and community practice, not published evidence. What the trial record does offer is a clear map of the side effects that cause people to stop — and they cluster at two predictable moments. Knowing those moments in advance, and knowing that dosing is a decision your prescribing clinician makes and adjusts with you, is most of what separates a protocol that holds together from one that gets abandoned in week seven.

What is tesamorelin, and what was 2 mg designed to do?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Rather than supplying growth hormone from outside, it signals the pituitary to release more of its own — which is why it is described as working with the body’s existing axis rather than replacing it. It is the same GHRH-analog logic behind sermorelin, and the full mechanism is covered in what tesamorelin is. The FDA approved it in 2010, under the brand name EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, at a dose of 2 mg injected subcutaneously once daily (EGRIFTA prescribing information, FDA).

The evidence behind that approval is substantial by peptide-category standards. In a 26-week randomized placebo-controlled phase 3 trial of 412 patients, tesamorelin reduced visceral adipose tissue where placebo did not (Falutz et al., NEJM 2007). A pooled analysis of the two phase 3 programs — 806 patients randomized across both — confirmed the visceral fat reduction and the safety profile over 26 weeks with extension data (Falutz et al., JCEM 2010). A later randomized trial at Massachusetts General Hospital found reductions in both visceral fat and liver fat over 6 months (Stanley et al., JAMA 2014).

Every number in that record was generated at 2 mg daily, in a specific patient population. That matters for what comes next.

Why do longevity protocols run lower than 2 mg?

Use of tesamorelin for body-composition, metabolic, or recovery goals outside HIV-associated lipodystrophy is off-label. When it is dispensed through a compounding pharmacy, the preparation is also not the FDA-approved product — compounded medications are not reviewed by the FDA for safety or effectiveness. Both facts should be plainly disclosed to any patient considering it, and both are part of the conversation a prescribing clinician should be having.

Within that off-label context, many clinicians start below 2 mg — and patient communities widely report settling in the 0.75 to 1 mg range. The honest characterization of those numbers: they are not supported by dose-ranging trials for longevity endpoints, because those trials have not been done. The reasoning behind lower starting doses is tolerability. The side effects documented at 2 mg — fluid retention, joint aches, and nerve-compression symptoms — are the class effects of raising growth hormone activity, and the standard clinical logic for any such medication is to start low, watch, and titrate deliberately. That is inference from pharmacology and practice, not a measured result, and it is your prescribing clinician’s call to make for your physiology — not a number to copy from a forum.

The first moment people quit: fluid effects in the early weeks

In the phase 3 program, the most commonly reported adverse reactions were arthralgia — joint pain, in 13.3% of tesamorelin patients versus 11.0% on placebo — along with injection-site redness and itching, pain in the extremities (6.1% vs 4.6%), peripheral edema, and myalgia (5.5% vs 1.9%) (EGRIFTA prescribing information, FDA). The label groups several of these under one mechanism: symptoms consistent with fluid retention, which growth hormone is known to cause.

Two things are worth holding onto. First, this is the expected early texture of the medication for a meaningful minority of patients — puffiness, joint stiffness, a watery heaviness — and it typically shows up in the opening weeks, which is precisely when a new patient is deciding whether the protocol is “working.” Second, the label states these reactions are either transient or resolve when treatment stops. Discontinuations due to adverse reactions in the trials ran 9.6% on tesamorelin versus 6.8% on placebo — a real difference, but a modest one. Most people who experience the early fluid effects and stay in contact with their clinician get through them.

The second moment: tingling and numbness, weeks in

The trial record also documents a second, later-arriving cluster: paresthesia — tingling or prickling sensations — in 4.8% of tesamorelin patients versus 2.3% on placebo; hypoesthesia, or numbness, in 4.2% versus 1.5%; and carpal tunnel syndrome in 1.5% versus none on placebo (EGRIFTA prescribing information, FDA). These are recognized effects of increased growth hormone activity — fluid retention narrowing the space around nerves, most noticeably in the wrists and hands.

Patient community reports describe the same phenomenon at lower doses than the trials used, with numbness and tingling in the hands and feet emerging somewhere in the middle weeks of a protocol and persisting for a stretch before resolving or prompting a dose change. Treat that timing as anecdote — it has not been characterized in a study — but the underlying effect is well documented, and the practical guidance does not depend on the exact week: new numbness, tingling, or hand weakness on tesamorelin is a report-it-now symptom, not a push-through symptom. Per the label, these reactions resolve with discontinuation, and a clinician has options short of stopping — holding the dose, lowering it, or pausing and re-challenging. What turns this side effect into a quit is usually silence: the patient doesn’t mention it, assumes it is permanent damage or a personal failure, and abandons the protocol alone. It is neither. It is a known, dose-related, reversible effect that your clinician should hear about the week it appears.

What monitoring should look like

Tesamorelin raises IGF-1, the downstream signal of growth hormone activity, and the label instructs clinicians to monitor IGF-1 regularly in all patients and to consider stopping if elevations persist (EGRIFTA prescribing information, FDA). Glucose deserves the same attention: the label warns that glucose intolerance may develop, and in the Massachusetts General trial fasting glucose rose measurably at two weeks before attenuating by six months (Stanley et al., JAMA 2014). The label also lists circumstances where tesamorelin should not be used at all — including active malignancy, disruption of the hypothalamic-pituitary axis, and pregnancy.

A supervised protocol should therefore look like this: baseline labs before the first injection, IGF-1 and glucose rechecked on a schedule your clinician sets, and a standing channel to report the two side-effect clusters above. If a program offers tesamorelin without lab monitoring attached, that is not a lighter version of the same care. It is a different product.

What happens when you stop

The extension data answers this directly. Patients who stayed on tesamorelin for a full 12 months held their visceral fat reduction — about 17.5% from baseline — while patients switched to placebo after 6 months saw visceral fat climb back toward where it started (Falutz et al., extension data 2010). Tesamorelin is maintenance pharmacology, not a course you complete: the effect persists while the signal persists. That is not a criticism — the same is true of most medications for structural, ongoing physiology — but it belongs in the decision before the first vial, not as a surprise at month seven. Duration, off-ramps, and what “worth continuing” would look like in your own labs are plan-level questions to settle with your clinician up front. If your underlying goal is deep abdominal fat rather than tesamorelin specifically, it is worth reading how it compares with GLP-1 medications in peptides for visceral fat and GLP-1, and how it differs from its shorter cousin in sermorelin vs tesamorelin.

How Trellis approaches tesamorelin dosing

Trellis Vitality is the accessibly-priced, patient-first alternative to premium-gated longevity clinics — on-demand and at home, without a five-figure annual membership. Where tesamorelin fits a patient, it is prescribed through a licensed clinical flow and, for non-HIV use, dispensed as a compounded medication with the off-label status stated plainly — and the dose is set and adjusted by the prescribing clinician, never copied from a protocol screenshot.

Every protocol begins with a free Vitality Lab Kit and baseline labs — including IGF-1 and metabolic markers — so the decision to start, to titrate, and to continue is anchored to your own numbers, and the two side-effect clusters above have a place to be reported the week they appear rather than a reason to quit alone.

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; other uses are off-label. For non-HIV use it is prescribed and, where compounded, prepared by a state-licensed, FDA-regulated compounding pharmacy. Compounded medications are not FDA-approved as finished products, and nothing here is a promise of results or a treatment for any disease. Dosing is decided within a licensed clinical relationship. This article is educational and is not medical advice.

Tesamorelin dosing FAQ

What is the standard tesamorelin dose? The only dose studied in large randomized trials is 2 mg injected subcutaneously once daily, and it was tested specifically for excess abdominal fat in HIV-associated lipodystrophy. Lower doses used in longevity settings are off-label clinical judgment, not a separately trial-proven protocol.

Why do some protocols use less than 2 mg? Tolerability. The side effects seen at 2 mg — fluid retention, joint aches, and nerve-compression symptoms — are class effects of raising growth-hormone activity, and standard practice is to start low and titrate. The commonly reported 0.75 to 1 mg figures are community practice, not dose-ranging trial results, and the right dose is your clinician’s call.

What are the main side effects of tesamorelin? In the phase 3 program the most common were joint pain, injection-site reactions, fluid retention (swelling and muscle aches), and nerve-compression symptoms such as tingling, numbness, and carpal tunnel syndrome. The label states these reactions are generally transient or resolve when treatment stops.

Does tesamorelin’s effect last after you stop? No. It is maintenance pharmacology — in the trials, the visceral-fat reduction held while treatment continued and climbed back toward baseline after patients switched to placebo. Duration and off-ramps are decisions to settle with your clinician before starting.

What monitoring does tesamorelin require? The label instructs regular IGF-1 monitoring and attention to glucose, on top of baseline labs before the first injection. It should not be used in active malignancy, disruption of the pituitary axis, or pregnancy. A program that offers tesamorelin without lab monitoring attached is a different product, not a lighter version of the same care.

The measured way to decide is to look at your own numbers first. Begin your assessment →

Sources

Chief Medical Officer: Shannon Arora, MD

Shannon Arora, MD is the Chief Medical Officer of Trellis Vitality. This is a statement of role, not a review of this specific article.

Related reading